Bio-Thera Solutions, Ltd.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 688177.SS | BHVN | 1777.TWO | PTGX | SYRE | ROIV | |
|---|---|---|---|---|---|---|
| Market cap | 7.12B | 1.72B | 3.39B | 8.71B | 8.01B | 25.11B |
| P/E (TTM) | — | — | 10.3 | 130.7 | — | — |
| Forward P/E | -25.3 | -6.1 | — | -879.0 | -24.3 | -20.2 |
| Price/book | 57.5 | 140.6 | 1.3 | 10.3 | 7.9 | 5.9 |
| Dividend yield | — | — | 5.22% | — | — | — |
| 1-year change | −36.71% | −38.54% | +4.07% | +67.82% | +240.14% | +89.01% |
| Today | +1.54% | +5.66% | −0.78% | +4.54% | +7.22% | +3.67% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All 688177.SS news ›Bio-Thera Solutions and Avalon Pharma are deepening their collaboration on BAT2406 in Saudi Arabia and other Middle Eastern and North African markets
Bio-Thera Solutions, Ltd. announced a deepened collaboration with Avalon Pharmaceuticals on BAT2406, a biosimilar of Dupixent dupilumab, in Saudi Arabia and other Middle Eastern and North African... announced a deepened collaboration with…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
marketscreener.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 1 articles, not a forecast.